Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)’. The study aims to assess the safety and effectiveness of the investigational drug ABBV-CLS-628 in treating ADPKD, a common genetic kidney disease characterized by fluid-filled cysts.
The intervention being tested is ABBV-CLS-628, administered intravenously. This drug is designed to treat ADPKD by potentially reducing the formation of cysts in the kidneys. Participants will receive either one of three doses of ABBV-CLS-628 or a placebo every four weeks over a 92-week period.
The study employs a randomized, parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the group assignments. The primary purpose of this study is treatment-focused.
The study began on March 25, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 26, 2025, indicating ongoing recruitment efforts.
This clinical study update could influence AbbVie’s stock performance positively if the results demonstrate significant efficacy and safety of ABBV-CLS-628. Investors should monitor this study closely, as successful outcomes could enhance AbbVie’s competitive position in the pharmaceutical industry, particularly in the nephrology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.